GW Pharmaceuticals

GW is a Cambridge-based biopharmaceutical company that researches and markets cannabinoid medicine for the treatment of LGS and Dravet syndrome. Read more

Justin Gover's photo - CEO of GW Pharmaceuticals

CEO

Justin Gover

CEO Approval Rating

86/100

Founded:

1998

Status:

PublicAcquired by Jazz Pharmaceuticals PlcNASDAQGWPH

GW PHARMACEUTICALS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Zynerba has been one of GW Pharmaceuticals's top competitors. Zynerba is a Public company that was founded in 2007 in Devon, Pennsylvania. Like GW Pharmaceuticals, Zynerba also competes in the Biotechnology sector. Compared to GW Pharmaceuticals, Zynerba has 470 fewer employees.

Zogenix is seen as one of GW Pharmaceuticals's biggest rivals. Zogenix is a Public company that was founded in San Diego, California in 2006. Like GW Pharmaceuticals, Zogenix also operates in the Biotechnology sector. Zogenix has 278 fewer employees vs. GW Pharmaceuticals.

Ovid is perceived as one of GW Pharmaceuticals's biggest rivals. Ovid was founded in New York, New York} in 2014. Like GW Pharmaceuticals, Ovid also competes in the Biotechnology space. Compared to GW Pharmaceuticals, Ovid generates $282.7M less revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is InMed a competitor of GW Pharmaceuticals?

GW Pharmaceuticals Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$559M

GW Pharmaceuticals's revenue is the ranked 2nd among it's top 10 competitors. The top 10 competitors average 230.2M. Over the last four quarters, GW Pharmaceuticals's revenue has grown by 25.7%. Specifically, in Q1 2021's revenue was $152.5M; in Q4 2020, it was $148.2M; in Q3 2020, it was $137.1M; in Q2 2020, GW Pharmaceuticals's revenue was $121.3M.

GW Pharmaceuticals Acquisitions

No recent acquisitions found related to GW Pharmaceuticals

GW Pharmaceuticals Funding History

Since GW Pharmaceuticals was founded in 1998, it has participated in 1 round of funding. In total GW Pharmaceuticals has raised $31.0M. GW Pharmaceuticals' funding round was on Apr 2013 for a total of $31.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Apr 2013
$31M
-

Since GW Pharmaceuticals was founded in 1998, it has participated in 1 round of funding. In total GW Pharmaceuticals has raised $31.0M. GW Pharmaceuticals' funding round was on Apr 2013 for a total of $31.0M

GW Pharmaceuticals Investments

No recent investments found related to GW Pharmaceuticals

GW Pharmaceuticals News

May 5, 2021BioSpace

Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc

Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceu... See more »
April 29, 2021FinanzNachrichten

GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen's Award for Enterprise in Innovation

GW's ground-breaking medicines development programme recognised for outstanding achievement in innova... See more »
April 23, 2021BioSpace

GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals

GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today a... See more »
April 21, 2021Pharmafile

GW Pharma's cannabidiol gains EC approval

GW Pharmaceuticals has received European Commission (EC) approval for the type II variation applicati... See more »
April 21, 2021PharmaTimes

GW Pharma's Epidyolex scores new EU indication

Cannabis-based medicine approved for the treatment of seizures associated with tuberous sclerosis com... See more »
April 20, 2021Proactive Investors

GW Pharmaceuticals says its cannabis-based treatment for seizures gets another regulatory green light in Europe

The approval paves the way for the expanded launch of the medicine across Europe for the treatment of... See more »

GW Pharmaceuticals Press Releases

November 5, 2019GlobeNewswire

GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019

- Epidiolex U.S. year to date net sales of $188.0 million, including Q3 net sales of $86.1 million --... See more »
November 26, 2018GlobeNewswire

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome

- Primary endpoint achieved with both EPIDIOLEX doses compared to placebo -... See more »
July 12, 2018BriefingWire

GWPH

PVP Research Chief Equity Analyst Thinks This Will Double over the next Year... See more »
July 12, 2018BriefingWire

GWPH

PVP Research Chief Equity Analyst Thinks This Will Double over the next Year... See more »
November 22, 2017EconoTimes

GW Pharmaceuticals to Present at Upcoming Investor Conferences

GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on ... See more »
October 16, 2017PR Newswire

Future Legal Cannabis Sales Projected to Rise

NEW YORK, October 16, 2017 /PRNewswire/ -- According to a forecast report by Arcview Market Research,... See more »

Social Media

GW Pharmaceuticals Headquarters

Sovereign House Vision Park, Histon

Cambridge, EnglandCB24 9BZ

44-1223-266800

Driving Directions »

Trending Companies

GW Pharmaceuticals Summary

ABOUT

Overview

GW is a Cambridge-based biopharmaceutical company that researches and markets cannabinoid medicine for the treatment of LGS and Dravet syndrome. GW Pharmaceuticals was founded in 1998. GW Pharmaceuticals' headquarters is located in Cambridge, England,...

CEO

GW Pharmaceuticals's CEO, Justin Gover, currently has an approval rating of 86%. GW Pharmaceuticals's primary competitors are Zynerba, Zogenix & Ovid.

Frequently Asked Questions about GW Pharmaceuticals

  1. When was GW Pharmaceuticals founded?

    GW Pharmaceuticals was founded in 1998
  2. Who is GW Pharmaceuticals's CEO?

    GW Pharmaceuticals's CEO is Justin Gover
  3. How much revenue does GW Pharmaceuticals generate?

    GW Pharmaceuticals generates $559M in revenue
  4. How much funding does GW Pharmaceuticals have?

    GW Pharmaceuticals has historically raised $31M in funding
  1. Where is GW Pharmaceuticals's headquarters?

    GW Pharmaceuticals's headquarters is in Cambridge England, GB
  2. How many employees does GW Pharmaceuticals have?

    GW Pharmaceuticals has 496 employees
  3. What sector does GW Pharmaceuticals operate in?

    GW Pharmaceuticals is in Biotechnology, Pharmaceuticals
  4. Who are GW Pharmaceuticals's competitors?

    GW Pharmaceuticals's top competitors are Zynerba, Zogenix, Ovid